The Added Value of Diagnostic and Theranostic PET Imaging for the Treatment of CNS Tumors

Pruis, Ilanah J.; van Dongen, Guus A. M. S.; Veldhuijzen van Zanten, Sophie E. M.

doi:10.3390/ijms21031029

Cited by 35Medical Imaging Techniques and ApplicationsRadiopharmaceutical Chemistry and ApplicationsGlioma Diagnosis and Treatment

The Added Value of Diagnostic and Theranostic PET Imaging for the Treatment of CNS Tumors

Open access

Pruis, Ilanah J., van Dongen, Guus A. M. S., Veldhuijzen van Zanten, Sophie E. M.·2020·International Journal of Molecular Sciences

DOI 10.3390/ijms21031029PMC PMC7037158

Open this paper in CoChat — free account Open PDF

Abstract

This review highlights the added value of PET imaging in Central Nervous System (CNS) tumors, which is a tool that has rapidly evolved from a merely diagnostic setting to multimodal molecular diagnostics and the guidance of targeted therapy. PET is the method of choice for studying target expression and target binding behind the assumedly intact blood–brain barrier. Today, a variety of diagnostic PET tracers can be used for the primary staging of CNS tumors and to determine the effect of therapy. Additionally, theranostic PET tracers are increasingly used in the context of pharmaceutical and radiopharmaceutical drug development and application. In this approach, a single targeted drug is used for PET diagnosis, upon the coupling of a PET radionuclide, as well as for targeted (nuclide) therapy. Theranostic PET tracers have the potential to serve as a non-invasive whole body navigator in the selection of the most effective drug candidates and their most optimal dose and administration route, together with the potential to serve as a predictive biomarker in the selection of patients who are most likely to benefit from treatment. PET imaging supports the transition from trial and error medicine to predictive, preventive, and personalized medicine, hopefully leading to improved quality of life for patients and more cost-effective care.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3390/ijms21031029

Cites

150 of 150 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Recent studies highlight the potential of nanoparticle-based radiopharmaceutical delivery systems in treating diseases, especially in cancer diagnosis and management.
“Recent studies highlight the potential of these systems in treating diseases, especially in cancer diagnosis and management [85].”
From Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation (2024) · cites this paper as [85]
Section 2 lists nanoparticles among agents used for theranostic PET and describes how radiopharmaceuticals can be used for cancer diagnosis and targeted therapy. But the paper focuses on CNS tumors and does not establish the claimed potential specifically for nanoparticle-based radiopharmaceutical delivery systems across diseases. The relevant passages have no page numbers in our copy. (LLM, conf=0.84)
Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Microenvironmental Landscape of Brain Tumors
Quail, D. F., & Joyce, J. A. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.009 · Cited by 1,875 · see citing works
The blood–brain barrier and blood–tumour barrier in brain tumours and metastases
Arvanitis, C., Ferraro, G. B., & Jain, R. K. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0205-x · Cited by 1,841 · see citing works
Untitled work
(1997) · PubMed · Cited by 1,541 · see citing works
225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer
Kratochwil, C., Bruchertseifer, F., Giesel, F. L., Weis, M., Verburg, F. A., Mottaghy, F. M., Kopka, K., Apostolidis, C., Haberkorn, U., & Morgenstern, A. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178673 · Cited by 1,163 · see citing works
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
van Tellingen, O., Yetkin-Arik, B., de Gooijer, M. C., Wesseling, P., Wurdinger, T., & de Vries, H. E. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.02.002 · Cited by 1,035 · see citing works
Cancer heterogeneity: implications for targeted therapeutics
Fisher, R. A., Pusztai, L., & Swanton, C. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.581 · Cited by 980 · see citing works
Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
Dijkers, E. C. F., Munnink, T. H. O., Kosterink, J. G. W., Brouwers, A. H., Jager, P. L., de Jong, J. R., van Dongen, G. A. M. S., Schroder, C. P., Hooge, M. N. L., & de Vries, E. G. E. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.12 · Cited by 810 · see citing works
Total-Body PET: Maximizing Sensitivity to Create New Opportunities for Clinical Research and Patient Care
Cherry, S. R., Jones, T., Karp, J. S., Qi, J., Moses, W. W., & Badawi, R. D. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.184028 · Cited by 763 · see citing works
Glucose utilization of cerebral gliomas measured by [ 18 F] fluorodeoxyglucose and positron emission tomography
Chiro, G. D., DeLaPaz, R. L., Brooks, R. A., Sokoloff, L., Kornblith, P. L., Smith, B. H., Patronas, N. J., Kufta, C. V., KESSLER, R. M., Johnston, G. S., et al. (1982) · Neurology · doi:10.1212/wnl.32.12.1323 · Cited by 746 · see citing works
Positron Emission Tomography-Computed Tomography Standardized Uptake Values in Clinical Practice and Assessing Response to Therapy
Kinahan, P. E., & Fletcher, J. W. (2010) · Seminars in Ultrasound, CT and MRI · doi:10.1053/j.sult.2010.10.001 · Cited by 631 · see citing works
The molecular biology of cancer
Bertram, J. S. (2000) · Molecular Aspects of Medicine · doi:10.1016/s0098-2997(00)00007-8 · Cited by 592 · see citing works
Radiolabeled amino acids: basic aspects and clinical applications in oncology.
Jager, P. L., Vaalburg, W., Pruim, J., et al. (2001) · PubMed · Cited by 557 · see citing works
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with <sup>225</sup>Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding
Kratochwil, C., Bruchertseifer, F., Rathke, H., Bronzel, M., Apostolidis, C., Weichert, W., Haberkorn, U., Giesel, F. L., & Morgenstern, A. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191395 · Cited by 505 · see citing works
Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen, W., Cloughesy, T. F., Kamdar, N. V., Satyamurthy, N., Bergsneider, M., Liau, L. M., Mischel, P. S., Czernin, J., Phelps, M. E., & Silverman, D. H. S. (2005) · PubMed · Cited by 437 · see citing works
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control
Kratochwil, C., Bruchertseifer, F., Rathke, H. G., Hohenfellner, M., Giesel, F. L., Haberkorn, U., & Morgenstern, A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.203539 · Cited by 429 · see citing works
Prediction of survival in glioma patients by means of positron emission tomography
Patronas, N. J., Chiro, G. D., Kufta, C. V., Bairamian, D., Kornblith, P. L., Simon, R. M., & Larson, S. M. (1985) · Journal of neurosurgery · doi:10.3171/jns.1985.62.6.0816 · Cited by 403 · see citing works
225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
Sathekge, M. M., Bruchertseifer, F., Knoesen, O., Reyneke, F., Lawal, I. O., Lengana, T., Davis, C., Mahapane, J., Corbett, C., Vorster, M., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4167-0 · Cited by 361 · see citing works
Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers.
DeGrado, T. R., BALDWIN, S. W., Wang, S., et al. (2001) · PubMed · Cited by 334 · see citing works
Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications
van Dongen, G. A. M. S., Visser, G. W. M., Hooge, M. N. L., de Vries, E. G. E., & Perk, L. R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-12-1379 · Cited by 331 · see citing works
Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo
Venneti, S., Dunphy, M. P., Zhang, H., Pitter, K. L., Zanzonico, P., Campos, C., Carlin, S., Rocca, G. L., Lyashchenko, S. K., Plöessl, K., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1009 · Cited by 314 · see citing works
A Prospective Evaluation of 18 F-FDG and 11 C-Acetate PET/CT for Detection of Primary and Metastatic Hepatocellular Carcinoma
Park, J., Kim, J. H., Kim, S. K., et al. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.055087 · Cited by 287 · see citing works
Value of 11C-methionine PET in imaging brain tumours and metastases
Glaudemans, A. W. J. M., Enting, R. H., Heesters, M. A. A. M., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2295-5 · Cited by 286 · see citing works
Hypoxia Positron Emission Tomography Imaging With 18F-Fluoromisonidazole
Lee, S. T., & Scott, A. M. (2007) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2007.07.001 · Cited by 283 · see citing works
Regional Hypoxia in Glioblastoma Multiforme Quantified with [18F]Fluoromisonidazole Positron Emission Tomography before Radiotherapy: Correlation with Time to Progression and Survival
Spence, A. M., Muzi, M., Swanson, K. R., O’Sullivan, F., Rockhill, J. K., Rajendran, J. G., Adamsen, T. C. H., Link, J. M., Swanson, P. E., Yagle, K. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4995 · Cited by 274 · see citing works
Brain tumour imaging with PET: a comparison between [ 18 F]fluorodopa and [ 11 C]methionine
Becherer, A., Karanikas, G., Szab�, M., Zettinig, G., Asenbaum, S., Marosi, C., Henk, C. B., Wunderbaldinger, P., Czech, T., Wadsak, W., et al. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1259-1 · Cited by 264 · see citing works
Molecular Mechanisms of Copper Homeostasis
Camakaris, J., Voskoboinik, I., & Mercer, J. F. B. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1073 · Cited by 256 · see citing works
An Interindividual Comparison of O-(2- [18F]Fluoroethyl)-L-Tyrosine (FET)– and L-[Methyl-11C]Methionine (MET)–PET in Patients With Brain Gliomas and Metastases
Grosu, A., Astner, S. T., Riedel, E., et al. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.07.002 · Cited by 254 · see citing works
18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors.
Jacobs, A. H., Thomas, A., Kracht, L., et al. (2005) · PubMed · Cited by 248 · see citing works
L ‐type amino acid transporter 1 as a potential molecular target in human astrocytic tumors
Nawashiro, H., Otani, N., Shinomiya, N., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21866 · Cited by 237 · see citing works
Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole.
Valk, P. E., Mathis, C. A., Prados, M. D., Gilbert, J. C., & Budinger, T. F. (1992) · PubMed · Cited by 224 · see citing works
Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study
Pafundi, D. H., Laack, N. N., Youland, R. S., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not002 · Cited by 218 · see citing works
Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O.
Bruehlmeier, M., Roelcke, U., Schubiger, P. A., & Ametamey, S. M. (2004) · PubMed · Cited by 216 · see citing works
Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO
Narayanaswami, V., Dahl, K., Bernard‐Gauthier, V., Josephson, L., Cumming, P. D., & Vasdev, N. (2018) · Molecular Imaging · doi:10.1177/1536012118792317 · Cited by 215 · see citing works
Synthesis of L- and D-[methyl-11C]methionine.
Långström, B., Antoni, G., Gullberg, P., et al. (1987) · PubMed · Cited by 214 · see citing works
Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas
Zikou, A. K., Sioka, C., Alexiou, G. Α., FOTOPOULOS, A. D., Voulgaris, S., & Argyropoulou, M. I. (2018) · Contrast Media & Molecular Imaging · doi:10.1155/2018/6828396 · Cited by 212 · see citing works
Molecular pathology of tumors of the central nervous system
Kristensen, B. W., Priesterbach-Ackley, L. P., Petersen, J. K., & Wesseling, P. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz164 · Cited by 211 · see citing works
The role of bevacizumab in the treatment of glioblastoma
Diaz, R. J., Ali, S. C., Qadir, M. G., de la Fuente, M. I., Ivan, M. E., & Komotar, R. J. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2477-x · Cited by 210 · see citing works
Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value
Laere, K. V., Ceyssens, S. K., Calenbergh, F. V., de Groot, T., Menten, J. J., Flamen, P., Bormans, G. M., & Mortelmans, L. A. (2004) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1564-3 · Cited by 207 · see citing works
68Ga-labeled DOTA-Peptides and 68Ga-labeled Radiopharmaceuticals for Positron Emission Tomography: Current Status of Research, Clinical Applications, and Future Perspectives
Breeman, W. A. P., de Blois, E., Chan, H. S., et al. (2011) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2011.02.001 · Cited by 203 · see citing works
Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases
Nomura, N., Pastorino, S., Jiang, P., et al. (2014) · Cancer Cell International · doi:10.1186/1475-2867-14-26 · Cited by 195 · see citing works
First-in-Human Human Epidermal Growth Factor Receptor 2–Targeted Imaging Using 89 Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer
Ulaner, G. A., Lyashchenko, S. K., Riedl, C. C., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.202010 · Cited by 179 · see citing works
The extracellular space and matrix of gliomas
Zámečnı́k, J. (2005) · Acta Neuropathologica · doi:10.1007/s00401-005-1078-5 · Cited by 174 · see citing works
Untitled work
(1995) · PubMed · Cited by 173 · see citing works
PET Imaging of human gliomas with ligands for the peripheral benzodiazepine binding site
Junck, L., Olson, J. M., Ciliax, B. J., Koeppe, R. A., Watkins, G. L., Jewett, D. M., McKeever, P. E., Wieland, D. M., Kilbourn, M. R., Starosta‐Rubinstein, S., et al. (1989) · Annals of Neurology · doi:10.1002/ana.410260611 · Cited by 167 · see citing works
Initial results of hypoxia imaging using 1-α-d-(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA)
Postema, E. J., McEwan, A. J. B., Riauka, T., Kumar, P., Richmond, D. A., Abrams, D. N., & Wiebe, L. I. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1154-5 · Cited by 164 · see citing works
Monoclonal antibodies in neuro-oncology
Lampson, L. A. (2011) · mAbs · doi:10.4161/mabs.3.2.14239 · Cited by 144 · see citing works
Treatment Response Evaluation Using 18F-FDOPA PET in Patients with Recurrent Malignant Glioma on Bevacizumab Therapy
von Schwarzenberg, J., Czernin, J. G., Cloughesy, T. F., Ellingson, B. M., Pope, W. B., Grogan, T., Elashoff, D. A., Geist, C. L., Silverman, D. H. S., Phelps, M. E., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1440 · Cited by 141 · see citing works
18F-FDG PET of Common Enhancing Malignant Brain Tumors
Kosaka, N., Tsuchida, T., Uematsu, H., et al. (2008) · American Journal of Roentgenology · doi:10.2214/ajr.07.2660 · Cited by 136 · see citing works
The promise of immuno-PET in radioimmunotherapy.
Verel, I., Visser, G. W. M., & van Dongen, G. A. (2005) · PubMed · Cited by 134 · see citing works
Somatostatin-receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68 Ga-DOTATATE/-TOC uptake
Seystahl, K., Stoecklein, V. M., Schüller, U., Rushing, E. J., Nicolas, G., Schäfer, N., Ilhan, H., Pangalu, A., Weller, M., Tonn, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now060 · Cited by 133 · see citing works
Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation in the Epidermal Growth Factor Receptor
Weber, B., Winterdahl, M., Memon, A. A., Sørensen, B. S., Keiding, S., Sørensen, L. H., Nexø, E., & Meldgaard, P. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318219ab87 · Cited by 131 · see citing works
Diagnostic Value of 68Ga PSMA-11 PET/CT Imaging of Brain Tumors—Preliminary Analysis
Sasikumar, A., Joy, A., Pillai, M. R. A., et al. (2016) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001451 · Cited by 129 · see citing works
Current status of PET imaging in neuro-oncology
Galldiks, N., Lohmann, P., Albert, N. L., Tonn, J. C., & Langen, K. (2019) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdz010 · Cited by 129 · see citing works
Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET
Kebir, S., Fimmers, R., Galldiks, N., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1334 · Cited by 127 · see citing works
Brain tumour imaging with carbon-11 choline: comparison with FDG PET and gadolinium-enhanced MR imaging
Ohtani, T., Kurihara, H., Ishiuchi, S., Saito, N., Oriuchi, N., Inoue, T., & Sasaki, T. (2001) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590100620 · Cited by 123 · see citing works
ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI
Gerstner, E. R., Zhang, Z., Fink, J. R., Muzi, M., Hanna, L., Greco, E. M., Prah, M. A., Schmainda, K. M., Mintz, A., Kostakoglu, L., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2529 · Cited by 122 · see citing works
Comparative Evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for Metabolic Imaging of Low Grade Gliomas
Tripathi, M., Sharma, R., D'Souza, M. M., Jaimini, A., Panwar, P., Varshney, R., Datta, A., Kumar, N., Garg, G., Singh, D., et al. (2009) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e3181becfe0 · Cited by 120 · see citing works
Non-invasive metabolic imaging of brain tumours in the era of precision medicine
Kim, M. M., Parolia, A., Dunphy, M. P., & Venneti, S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.108 · Cited by 119 · see citing works
PET study of carbon-11-PK 11195 binding to peripheral type benzodiazepine sites in glioblastoma: a case report.
Pappatà, S., Cornu, P., Samson, Y., Prenant, C., Bénavidès, J., Scatton, B., Crouzel, C., Hauw, J., & Syrota, A. (1991) · PubMed · Cited by 116 · see citing works
TSPO PET for glioma imaging using the novel ligand 18F-GE-180: first results in patients with glioblastoma
Albert, N. L., Unterrainer, M., Fleischmann, D. F., Lindner, S., Vettermann, F. J., Brunegraf, A., Vomacka, L., Brendel, M., Wenter, V., Wetzel, C. H., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3799-9 · Cited by 115 · see citing works
64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
Kurihara, H., Hamada, A., Yoshida, M., et al. (2015) · EJNMMI Research · doi:10.1186/s13550-015-0082-6 · Cited by 112 · see citing works
18F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas
Hirata, K., Terasaka, S., Shiga, T., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-2037-0 · Cited by 111 · see citing works
Immunohistochemical expression of peripheral benzodiazepine receptors in human astrocytomas and its correlation with grade of malignancy, proliferation, apoptosis and survival
Vlodavsky, E., & Soustiel, J. F. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9199-9 · Cited by 111 · see citing works
Osmotic opening of the blood‐brain barrier and local cerebral glucose utilization
Pappius, H. M., Savaki, H. E., Fieschi, C., Рапопорт, С. И., & Sokoloff, L. (1979) · Annals of Neurology · doi:10.1002/ana.410050302 · Cited by 111 · see citing works
Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma
Królicki, L., Bruchertseifer, F., Kunikowska, J., Koziara, H. M., Królicki, B., Jakuciński, M., Pawlak, D., Apostolidis, C., Mirzadeh, S., Rola, R., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4225-7 · Cited by 109 · see citing works
Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with 213Bi-substance P analogue
Królicki, L., Bruchertseifer, F., Kunikowska, J., Koziara, H. M., Królicki, B., Jakuciński, M., Pawlak, D., Apostolidis, C., Mirzadeh, S., Rola, R., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4015-2 · Cited by 108 · see citing works
Relation of LAT1/4F2hc expression with pathological grade, proliferation and angiogenesis in human gliomas
Haining, Z., Kawai, N., Miyake, K., et al. (2012) · BMC Clinical Pathology · doi:10.1186/1472-6890-12-4 · Cited by 106 · see citing works
Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation.
Tralins, K. S., Douglas, J. G., Stelzer, K. J., et al. (2002) · PubMed · Cited by 101 · see citing works
Total-Body PET and Highly Stable Chelators Together Enable Meaningful 89Zr-Antibody PET Studies up to 30 Days After Injection
Berg, E., Gill, H. S., Mařı́k, J., Ogasawara, A. K., Williams, S. P., van Dongen, G. A. M. S., Vugts, D. J., Cherry, S. R., & Tarantal, A. F. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.230961 · Cited by 100 · see citing works
PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET
van Dongen, G. A. M. S., Poot, A. J., & Vugts, D. J. (2012) · Tumor Biology · doi:10.1007/s13277-012-0316-4 · Cited by 97 · see citing works
Engineered antibodies: new possibilities for brain PET?
Sehlin, D., & Syvänen, S. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04426-0 · Cited by 96 · see citing works
Molecular Drug Imaging: 89Zr-Bevacizumab PET in Children with Diffuse Intrinsic Pontine Glioma
Jansen, M. H. A., van Zanten, S. E. M. V., van Vuurden, D. G., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.180216 · Cited by 89 · see citing works
18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma
Lee, J. W., Kang, K. W., Park, S. S., et al. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1133-x · Cited by 85 · see citing works
The 18-kDa Mitochondrial Translocator Protein in Human Gliomas: An 11C-(R)PK11195 PET Imaging and Neuropathology Study
Su, Z., Roncaroli, F., Durrenberger, P. F., Coope, D. J., Karabatsou, K., Hinz, R., Thompson, G., Turkheimer, F., Janczar, K., du Plessis, D., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.151621 · Cited by 84 · see citing works
Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89Zr-Df-IAB2M anti-PSMA minibody
Matsuda, M., Ishikawa, E., Yamamoto, T., et al. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2825-5 · Cited by 84 · see citing works
Study of LAT1 Expression in Brain Metastases: Towards a Better Understanding of the Results of Positron Emission Tomography Using Amino Acid Tracers
Papin-Michault, C., Bonnetaud, C., Dufour, M., Almairac, F., Coutts, M., Patouraux, S., Virolle, T., Darcourt, J., & Burel‐Vandenbos, F. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157139 · Cited by 82 · see citing works
The Role of Neurokinin-1 Receptor in the Microenvironment of Inflammation and Cancer
Rosso, M., Muñoz, M., & Berger, M. (2012) · The Scientific World JOURNAL · doi:10.1100/2012/381434 · Cited by 79 · see citing works
Radretumab Radioimmunotherapy in Patients with Brain Metastasis: A 124I-L19SIP Dosimetric PET Study
Poli, G. L., Bianchi, C., Virotta, G., Bettini, A., Moretti, R., Trachsel, E., Elia, G., Giovannoni, L., Neri, D., & Bruno, A. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0007 · Cited by 78 · see citing works
Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer
Saleem, A., Searle, G. E., Kenny, L. M., Huiban, M., Kozlowski, K., Waldman, A. D., Woodley, L., Palmieri, C., Lowdell, C. P., Kaneko, T., et al. (2015) · EJNMMI Research · doi:10.1186/s13550-015-0103-5 · Cited by 78 · see citing works
11C-Acetate PET in the Evaluation of Brain Glioma: Comparison with 11C-Methionine and 18F-FDG-PET
Yamamoto, Y., Nishiyama, Y., Kimura, N., Kameyama, R., Kawai, N., Hatakeyama, T., Kaji, M., & Ohkawa, M. (2008) · Molecular Imaging and Biology · doi:10.1007/s11307-008-0152-5 · Cited by 74 · see citing works
TSPO expression in brain tumours: is TSPO a target for brain tumour imaging?
Roncaroli, F., Su, Z., Herholz, K., Gerhard, A., & Turkheimer, F. (2016) · Clinical and Translational Imaging · doi:10.1007/s40336-016-0168-9 · Cited by 74 · see citing works
Grading of brain glioma with 1-11C-acetate PET: comparison with 18F-FDG PET
Tsuchida, T., Takeuchi, H., Okazawa, H., Tsujikawa, T., & Fujibayashi, Y. (2008) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2007.11.004 · Cited by 72 · see citing works
Companion diagnostics—a tool to improve pharmacotherapy
Jørgensen, J. T., & Hersom, M. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.12.26 · Cited by 71 · see citing works
PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET
Slobbe, P., Poot, A. J., Windhorst, A. D., & van Dongen, G. A. M. S. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.06.016 · Cited by 70 · see citing works
A Distinct Advantage to Intraarterial Delivery of 89Zr-Bevacizumab in PET Imaging of Mice With and Without Osmotic Opening of the Blood–Brain Barrier
Lesniak, W. G., Chu, C., Jabłońska, A., Du, Y., Pomper, M. G., Walczak, P., & Janowski, M. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.218792 · Cited by 70 · see citing works
Molecular Targeted α-Particle Therapy for Oncologic Applications
Wadas, T. J., Pandya, D. N., Sai, K. K. S., & Mintz, A. (2014) · American Journal of Roentgenology · doi:10.2214/ajr.14.12554 · Cited by 65 · see citing works
Response of Recurrent High-Grade Glioma to Treatment with 90Y-DOTATOC
Heute, D., Kostron, H., von Guggenberg, E., et al. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.072819 · Cited by 65 · see citing works
Hypoxia Imaging in Gliomas With 18F-Fluoromisonidazole PET: Toward Clinical Translation
Bell, C., Dowson, N., Fay, M., Thomas, P. A., Puttick, S. G., Gal, Y., & Rose, S. (2015) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2014.10.001 · Cited by 65 · see citing works
Hypoxia Imaging and Adaptive Radiotherapy: A State-of-the-Art Approach in the Management of Glioma
Gérard, M., Corroyer‐Dulmont, A., Lesueur, P., Collet, S., Chérel, M., Bourgeois, M., Stefan, D., Limkin, E. J., Perrio, C., Guillamo, J., et al. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00117 · Cited by 64 · see citing works
Imaging of Brain Tumors with Copper-64 Chloride: Early Experience and Results
Panichelli, P., Villano, C., Cistaro, A., et al. (2016) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2016.2028 · Cited by 62 · see citing works
Radiolabeled inorganic nanoparticles for positron emission tomography imaging of cancer: an overview
Chakravarty, R., Goel, S., Dash, A. K., & Cai, W. (2017) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.17.02969-7 · Cited by 61 · see citing works
Prostate-Specific Membrane Antigen–Targeted Imaging With [18F]DCFPyL in High-Grade Gliomas
Fragomeni, R. A. S., Menke, J. R., Holdhoff, M., et al. (2017) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001769 · Cited by 61 · see citing works
Toward Radioguided Surgery with β− Decays: Uptake of a Somatostatin Analogue, DOTATOC, in Meningioma and High-Grade Glioma
Collamati, F., Pepe, A., Bellini, F., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.145995 · Cited by 60 · see citing works
18F-FET-PET guided surgical biopsy and resection in children and adolescence with brain tumors
Misch, M., Guggemos, A., Driever, P. H., et al. (2014) · Child s Nervous System · doi:10.1007/s00381-014-2552-y · Cited by 60 · see citing works
Amino acid PET and MR perfusion imaging in brain tumours
Filß, C., Cicone, F., Shah, N. J., et al. (2017) · Clinical and Translational Imaging · doi:10.1007/s40336-017-0225-z · Cited by 60 · see citing works
Comparison of 18F-GE-180 and dynamic 18F-FET PET in high grade glioma: a double-tracer pilot study
Unterrainer, M., Fleischmann, D. F., Diekmann, C., Vomacka, L., Lindner, S., Vettermann, F. J., Brendel, M., Wenter, V., Ertl-Wagner, B. B., Herms, J. W., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4166-1 · Cited by 60 · see citing works
Differential Uptake of 68Ga-PSMA-HBED-CC (PSMA-11) in Low-Grade Versus High-Grade Gliomas in Treatment-Naive Patients
Verma, P., Malhotra, G., Goel, A. H., Rakshit, S., Chandak, A., Chedda, R., Banerjee, S., & Asopa, R. V. (2019) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002520 · Cited by 60 · see citing works
Evaluation of Focal Cortical Dysplasia and Mixed Neuronal and Glial Tumors in Pediatric Epilepsy Patients Using 18 F-FDG and 11 C-Methionine PET
Phi, J. H., Paeng, J. C., Lee, H. S., et al. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.070920 · Cited by 59 · see citing works
[11C]-(R)PK11195 tracer kinetics in the brain of glioma patients and a comparison of two referencing approaches
Su, Z., Herholz, K., Gerhard, A., Roncaroli, F., du Plessis, D., Jackson, A., Turkheimer, F., & Hinz, R. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2447-2 · Cited by 58 · see citing works
1-11C-Acetate Versus 18F-FDG PET in Detection of Meningioma and Monitoring the Effect of γ-Knife Radiosurgery
Liu, R.-S., Chang, C.-P., Guo, W.-Y., et al. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.070565 · Cited by 57 · see citing works
Expression of PSMA in tumor neovasculature of high grade sarcomas including synovial sarcoma, rhabdomyosarcoma, undifferentiated sarcoma and MPNST
Heitkötter, B., Trautmann, M., Grünewald, I., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13994 · Cited by 57 · see citing works
A PET study in healthy subjects of brain exposure of 11 C-labelled osimertinib – A drug intended for treatment of brain metastases in non-small cell lung cancer
Varrone, A., Varnäs, K., Jučaitė, A., Cselényi, Z., Johnström, P., Schou, M., Vázquez‐Romero, A., Moein, M. M., Halldin, C., Brown, A. P., et al. (2019) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19843776 · Cited by 57 · see citing works
C-11 Choline Versus F-18 Fluorodeoxyglucose for Imaging Meningiomas
Giovacchini, G., Fallanca, F., Landoni, C., et al. (2008) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e31818f4369 · Cited by 55 · see citing works
Hybrid Imaging: Instrumentation and Data Processing
Cal-González, J., Rausch, I., Sundar, L. K. S., Lassen, M. L., Muzik, O., Moser, E., Papp, L., & Beyer, T. (2018) · Frontiers in Physics · doi:10.3389/fphy.2018.00047 · Cited by 52 · see citing works
Differentiation of recurrent astrocytoma from radiation necrosis: a pilot study with 13N-NH3 PET
Zhang, X., & Weian, C. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9286-y · Cited by 51 · see citing works
Clinical Applications of Choline PET/CT in Brain Tumors
Giovannini, E., Lazzeri, P., Milano, A., Gaeta, M. C., & Ciarmiello, A. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666140915120742 · Cited by 49 · see citing works
PET imaging of distinct brain uptake of a nanobody and similarly-sized PAMAM dendrimers after intra-arterial administration
Lesniak, W. G., Chu, C., Jabłońska, A., Azad, B. B., Zwaenepoel, O., Zawadzki, M., Lisok, A., Pomper, M. G., Walczak, P., Gettemans, J., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04347-y · Cited by 47 · see citing works
Clinical characteristics of meningiomas assessed by 11C-methionine and 18F-fluorodeoxyglucose positron-emission tomography
Arita, H., Kinoshita, M., Okita, Y., et al. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0759-2 · Cited by 44 · see citing works
PET: Blood flow and oxygen consumption in brain tumors
Leenders, K. L. (1994) · Journal of Neuro-Oncology · doi:10.1007/bf01052932 · Cited by 44 · see citing works
Misdiagnoses of 11C-choline combined with 18F-FDG PET imaging in brain tumours
Huang, Z., Zuo, C., Guan, Y., Zhang, Z., Liu, P., Xue, F., & Lin, X. (2008) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e3282f4a21e · Cited by 43 · see citing works
PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-Prostate Carcinoma: A Systematic Review
de Wiele, C. V., Sathekge, M. M., Spiegeleer, B. M. J. D., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194886 · Cited by 43 · see citing works
MRI-Driven PET Image Optimization for Neurological Applications
Zhu, Y., & Zhu, X. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00782 · Cited by 42 · see citing works
Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate Cancer
Wei, X. X., Schlenkhoff, C. D., Schwarz, B., et al. (2017) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001763 · Cited by 39 · see citing works
The roles of 11C-acetate PET/CT in predicting tumor differentiation and survival in patients with cerebral glioma
Kim, S., Kim, D., Kim, S. H., Park, M., Chang, J. H., & Yun, M. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-3948-9 · Cited by 37 · see citing works
Clinical use of 11C-methionine and 18F-FDG-PET for germinoma in central nervous system
Okochi, Y., Nihashi, T., Fujii, M., et al. (2013) · Annals of Nuclear Medicine · doi:10.1007/s12149-013-0787-4 · Cited by 36 · see citing works
Glioblastoma multiforme: another potential application for 68Ga-PSMA PET/CT as a guide for targeted therapy
Kunikowska, J., Królicki, B., & Królicki, L. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-3934-2 · Cited by 36 · see citing works
Prevalence of hitherto unknown brain meningioma detected on 68Ga-DOTATATE positron-emission tomography/computed tomography in patients with metastatic neuroendocrine tumor and exploring potential of 177Lu-DOTATATE peptide receptor radionuclide therapy as single-shot treatment approach targeting both tumors
Parghane, R. V., Talole, S. D., & Basu, S. K. (2019) · World Journal of Nuclear Medicine · doi:10.4103/wjnm.wjnm_39_18 · Cited by 36 · see citing works
Current Radiopharmaceuticals for Positron Emission Tomography of Brain Tumors
Jung, J., & Ahn, B. (2018) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2018.6.e13 · Cited by 35 · see citing works
Will 177Lu-DOTATATE Treatment Become More Effective in Salvage Meningioma Patients, When Boosting Somatostatin Receptor Saturation? A Promising Case on Intra-arterial Administration
Braat, A. J. A. T., Snijders, T. J., Seute, T., et al. (2019) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-019-02262-1 · Cited by 34 · see citing works
Diagnostic accuracy of 13N-ammonia PET, 11C-methionine PET and 18F-fluorodeoxyglucose PET: a comparative study in patients with suspected cerebral glioma
He, Q. J., Zhang, L., Zhang, B. M., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5560-1 · Cited by 32 · see citing works
In-vivo imaging of blood–brain barrier permeability using positron emission tomography with 2-amino-[3-11C]isobutyric acid
Okada, M., Kikuchi, T., Okamura, T., et al. (2015) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000385 · Cited by 28 · see citing works
Standardized Uptake Value in High Uptake Area on Positron Emission Tomography with 18F-FRP170 as a Hypoxic Cell Tracer Correlates with Intratumoral Oxygen Pressure in Glioblastoma
Beppu, T., Terasaki, K., Sasaki, T., Fujiwara, S., Matsuura, H., Ogasawara, K., Sera, K., Yamada, N., Uesugi, N., Sugai, T., et al. (2013) · Molecular Imaging and Biology · doi:10.1007/s11307-013-0670-7 · Cited by 27 · see citing works
PET Imaging in Glioblastoma: Use in Clinical Practice
Verger, A., & Langen, K. (2017) · Codon Publications eBooks · doi:10.15586/codon.glioblastoma.2017.ch9 · Cited by 27 · see citing works
Imaging Brain Metastasis Patients With 18F-(2S,4R)-4-Fluoroglutamine
Xu, X., Zhu, H., Liu, F., Zhang, Y., Yang, J., Zhang, L., Zhu, L., Li, N., Kung, H. F., & Yang, Z. (2018) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002257 · Cited by 27 · see citing works
The endothelial prostate-specific membrane antigen is highly expressed in gliosarcoma and visualized by [68Ga]-PSMA-11 PET: a theranostic outlook for brain tumor patients?
Unterrainer, M., Niyazi, M., Ruf, V., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox172 · Cited by 26 · see citing works
Immunolocalization of Full-length NK 1 Tachykinin Receptors in Human Tumors
Schulz, S., Schulz, S., Stumm, R. K., et al. (2006) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.6a6966.2006 · Cited by 25 · see citing works
13N-NH3 Versus F-18 FDG in Detection of Intracranial Meningioma
Xiangsong, Z., Xingchong, S., Chang, Y., et al. (2011) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e3182291c2a · Cited by 24 · see citing works
Expression of EAAT-1 distinguishes choroid plexus tumors from normal and reactive choroid plexus epithelium
Beschorner, R., Pantazis, G., Jeibmann, A., Boy, J., Meyermann, R., Mittelbronn, M. G. A., & Schittenhelm, J. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0519-y · Cited by 24 · see citing works
Imaging biomarkers in primary brain tumours
Lopci, E., Franzese, C., Grimaldi, M., Zucali, P. A., Navarria, P., Simonelli, M., Bello, L., Scorsetti, M., & Chiti, A. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2971-8 · Cited by 24 · see citing works
Transport across the blood-brain barrier: stereoselectivity and PET-tracers
Luurtsema, G., DELANGE, E., Lammertsma, A. A., & Franssen, E. J. F. (2004) · Molecular Imaging and Biology · doi:10.1016/j.mibio.2004.06.008 · Cited by 24 · see citing works
Prognostic implications of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET/CT in patients with glioma
Toriihara, A., Ohtake, M., Tateishi, K., Hino-Shishikura, A., Yoneyama, T., Kitazume, Y., Inoue, T., Kawahara, N., & Tateishi, U. (2018) · Annals of Nuclear Medicine · doi:10.1007/s12149-018-1241-4 · Cited by 21 · see citing works
Intraindividual comparison of selective intraarterial versus systemic intravenous 68Ga-DOTATATE PET/CT in patients with inoperable meningioma
Verburg, F. A., Wiessmann, M., Neuloh, G., et al. (2019) · Nuklearmedizin - NuclearMedicine · doi:10.1055/a-0802-5039 · Cited by 21 · see citing works
13N-NH3: a selective contrast-enhancing tracer for brain tumor
Zhang, X., Wu, X.-J., Zhang, Y., et al. (2008) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e328310af34 · Cited by 20 · see citing works
18F-FAZA PET/CT Hypoxia Imaging of High-Grade Glioma Before and After Radiotherapy
Mapelli, P., Zerbetto, F., Incerti, E., et al. (2017) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001850 · Cited by 20 · see citing works
PET imaging in glioma
Mansoor, N. M., Thust, S. C., Militano, V., et al. (2018) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000914 · Cited by 20 · see citing works
Use of Positron Emission Tomography in the Evaluation of Diffuse Intrinsic Brainstem Gliomas in Children
Rosenfeld, A., Etzl, M., Bandy, D., et al. (2011) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e31820ad915 · Cited by 19 · see citing works
Quatitation of blood-brain barrier permiability by positron emission tomography
Webb, S., Ott, R. J., & Cherry, S. R. (1989) · Physics in Medicine and Biology · doi:10.1088/0031-9155/34/12/001 · Cited by 18 · see citing works
Brain Access of Monoclonal Antibodies as Imaged and Quantified by 89Zr-Antibody PET: Perspectives for Treatment of Brain Diseases
van Zanten, S. E. M. V., Hamer, P. C. D. W., & van Dongen, G. A. M. S. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.220939 · Cited by 18 · see citing works
Perfusion-metabolism coupling in recurrent gliomas: a prospective validation study with 13N-ammonia and 18F-fluorodeoxyglucose PET/CT
Khangembam, B. C., Karunanithi, S., Sharma, P., Sudhir Suman, K. C., Kumar, R., Julka, P. K., Kumar, R., & Bal, C. (2014) · Neuroradiology · doi:10.1007/s00234-014-1389-0 · Cited by 17 · see citing works
High-uptake areas on positron emission tomography with the hypoxic radiotracer 18F-FRP170 in glioblastomas include regions retaining proliferative activity under hypoxia
Beppu, T., Sasaki, T., Terasaki, K., Saura, H., Mtsuura, H., Ogasawara, K., Sasaki, M., Ehara, S., Iwata, R., & Takai, Y. (2015) · Annals of Nuclear Medicine · doi:10.1007/s12149-015-0951-0 · Cited by 14 · see citing works
Principles and current trends in the correlative evaluation of glioma with advanced MRI techniques and PET
Tsiouris, S., Bougias, H., & FOTOPOULOS, A. D. (2020) · PubMed · Cited by 14 · see citing works
Methionine and Glucose Metabolism of Central Neurocytoma: A PET Study
Takao, H., Momose, T., & Ohtomo, K. (2004) · Clinical Nuclear Medicine · doi:10.1097/00003072-200412000-00023 · Cited by 10 · see citing works
New metabolic imaging tools in neuro-oncology
Corbin, Z. A. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000758 · Cited by 10 · see citing works
PET for Therapy Response Assessment in Glioblastoma
Bolcaen, J., Acou, M., Descamps, B., et al. (2017) · Codon Publications eBooks · doi:10.15586/codon.glioblastoma.2017.ch10 · Cited by 9 · see citing works
Cerebellopontine Angle Schwannoma on C-11 Acetate PET/CT
Lee, S. M., Kim, T.-S., & Kim, S.-K. (2009) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e3181b81ce4 · Cited by 8 · see citing works
Expression of large neutral amino acid transporters LAT1 and LAT2 in medulloblastoma
Cicone, F., Minniti, G. C., Oliva, M. A., et al. (2017) · Brain Tumor Pathology · doi:10.1007/s10014-017-0296-6 · Cited by 7 · see citing works
Radioactive Iodine Treatment and Cancer Mortality in Hyperthyroid Patients: Questioning Standard Clinical Practice Requires Indisputable Scientific Data
Chen, W., & Dilsizian, V. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.234849 · Cited by 6 · see citing works
Valor de la PET/TC cerebral con 18 F-fluorocolina en la detección de recurrencias de neoplasias primarias del sistema nervioso central
Montes, A., Fernández, A., Camacho, V., et al. (2017) · Revista Española de Medicina Nuclear e Imagen Molecular · doi:10.1016/j.remn.2016.11.005 · Cited by 4 · see citing works
The usefulness of 18 F-fluorocholine PET/CT in the detection of recurrence of central nervous system primary neoplasms
Montes, A., Fernández, A., Camacho, V., et al. (2017) · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) · doi:10.1016/j.remnie.2017.03.001 · Cited by 4 · see citing works
Taxonomy of CNS tumours; a series of three short reviews on the WHO 2016 classification and beyond
Wesseling, P., & Jacques, T. S. (2017) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12442 · Cited by 4 · see citing works

Flagged first, then by citations

Sorted by citations

Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation
Dhoundiyal, S., Srivastava, S., Kumar, S., Singh, G., Ashique, S., Pal, R., Mishra, N., & Taghizadeh-Hesary, F. (2024) · European Journal of Medical Research · doi:10.1186/s40001-023-01627-0 · Cited by 144 · see citing works
“Recent studies highlight the potential of these systems in treating diseases, especially in cancer diagnosis and management [85].”
Background

The future of precision medicine: towards a more predictive personalized medicine
Elemento, O. (2020) · Emerging Topics in Life Sciences · doi:10.1042/etls20190197 · Cited by 67 · see citing works
HARNESSING THE POWER OF PERSONALIZED MEDICINES: STEPS AND INNOVATIONS
Singhal, P., & Natasha, M. (2023) · Iterative International Publishers eBooks · doi:10.58532/v3bjbt5p5ch3
TRANSFORMING HEALTHCARE WITH PRECISION MEDICINE: UNVEILING THE FUTURE OF PERSONALIZED TREATMENT
Moulik, A. K., Ratnam, R. S., Sriushaswini, B., et al. (2023) · doi:10.53555/jptcp.v30i17.2885
Detecting Personalized Determinants During Drug Treatment from Omics Big Data
Wang, L., Yu, X., Zhang, C., & Zeng, T. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612824666181106102111 · Cited by 10 · see citing works
Precision (personalized) medicine
Walton, N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95274-3.00002-6 · Cited by 3 · see citing works

Authors: Pruis, I. J., van Dongen, G. A. M. S., & Veldhuijzen van Zanten, S. E. M.
Affiliations: Erasmus MC (NL)
Department of Radiology & Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands
Department of Radiology & Nuclear Medicine, Erasmus MC, 3015 GD Rotterdam, The Netherlands
ORCID: Pruis, Ilanah J.
Veldhuijzen van Zanten, Sophie E. M.
Venue: International Journal of Molecular Sciences
Publisher: MDPI AG
Published: 2020-02-04
Volume: 21
Issue: 3
Pages: 1029
ISSN: 1422-0067 (ISSN-L)
DOI: 10.3390/ijms21031029
PMC: PMC7037158
OpenAlex: W3005120786
Cited by: 35
References: 150
Citations by year: 2026: 4 · 2025: 3 · 2024: 9 · 2023: 3 · 2022: 2 · 2021: 9 · 2020: 3 · 2019: 1
FWCI: 0.63
Type: journal article
Language: en
Open access: gold
dx.doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (vor)
Locations: International Journal of Molecular Sciences (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Pure Amsterdam UMC (publishedVersion, cc-by)
Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Topics: Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
Keywords: positron emission tomography, central nervous system tumors, targeted therapy, radiopharmaceuticals, treatment response monitoring, predictive biomarkers, personalized medicine, blood-brain barrier, tumor staging
MeSH terms: Theranostic Nanomedicine, Animals, Humans, Biomarkers, Central Nervous System Neoplasms, Radiopharmaceuticals, Positron-Emission Tomography, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Added Value of Diagnostic and Theranostic PET Imaging for the Treatment of CNS Tumors

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks